Verastem, Inc. (VSTM) Stock
Key stats
- Market cap
- $1.15B
- Price / Earnings ratio
- -6.1x
- EPS (TTM)
- -$1.75
- Volume
- Loading
- 52-week high
- $10.82
- 52-week low
- $3.43
Source: third-party data provider, as of November 13, 2026
Compare with VSTM
Recent news

Verastem Oncology to Participate in Upcoming November Investor Conferences
Verastem Oncology to Participate in Upcoming November Investor Conferences
VSTM

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
VSTM

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
VSTM

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
VSTM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.35
- MACD 12/26/9
- 0.17
- EMA 9 of MACD
- 0.34
- MACD histogram
- -0.17
- SMA 50
- $8.47
- Price above SMA 50
- EMA 50
- $8.48
- Price above EMA 50
- SMA 200
- $6.28
- Price above SMA 200
- EMA 200
- $7.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.57 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Verastem Oncology to Participate in Upcoming November Investor Conferences
Verastem Oncology to Participate in Upcoming November Investor Conferences
VSTM

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
VSTM

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
VSTM

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
VSTM

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
VSTM

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
VSTM

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
VSTM

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?
VSTM

Dow, S&P 500, Nasdaq Futures Climb After Oil In Focus As Trump Declares ‘Energy Ceasefire’ Between Russia And Ukraine: IREN, WFF, VSTM, CIFR Stocks In Focus
Dow, S&P 500, Nasdaq Futures Climb After Oil In Focus As Trump Declares ‘Energy Ceasefire’ Between Russia And Ukraine: IREN, WFF, VSTM, CIFR Stocks In Focus
VSTM

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
VSTM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Verastem, Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel W. Paterson | President, CEO & Director | 1961 |
| Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board | — |
| Mr. Daniel Calkins | Chief Financial Officer | 1988 |
| Dr. Michael Glen Kauffman M.D., Ph.D. | President of Development & Director | 1963 |
| Dr. Michelle Detwiler M.D., Ph.D. | Co-Founder | 1976 |
| Ms. Lori Horvat | Executive Vice President of Portfolio Strategy & Operations | — |
| Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer | 1958 |
| Mr. Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer | — |
| Ms. Cathy Carew | Chief Organizational Effectiveness Officer | — |
| Mr. Nathan Sanburn | Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.35
- MACD 12/26/9
- 0.17
- EMA 9 of MACD
- 0.34
- MACD histogram
- -0.17
- SMA 50
- $8.47
- Price above SMA 50
- EMA 50
- $8.48
- Price above EMA 50
- SMA 200
- $6.28
- Price above SMA 200
- EMA 200
- $7.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $13.00
- Average
- $17.80
- High
- $24.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -14.1 | -19.6 | ||||||||||
| 2022 | -27.1 | -23.6 | +17.5 | -0.7 | -11.7 | -7.2 | -5.3 | +7.4 | -26.1 | -52.0 | +5.7 | -7.5 |
| 2023 | +54.3 | -19.3 | -16.2 | +0.2 | +131.8 | -38.3 | +42.7 | -11.1 | -17.5 | -19.9 | +9.2 | +16.1 |
| 2024 | +41.6 | +1.7 | -9.4 | -14.9 | -60.3 | -24.4 | -20.0 | +2.9 | +23.6 | +33.3 | +36.2 | -6.3 |
| 2025 | -6.3 | -1.9 | +8.8 | +28.7 | +1.2 | -31.1 | +43.8 | +52.1 | -4.2 | +7.4 | +7.5 | -25.3 |
| 2026 | -15.6 | -8.5 | -8.9 | -1.6 | -25.9 | -8.8 | +41.5 | +26.9 | +5.8 | +23.4 | -5.2 |



